ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2019

Sep 15, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Exopharm Limited ABN: 78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Jason M Watson
Date of last notice	19 August 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	WatsonPractice	Company	Pty	Ltd
(including registered holder)	<Watson Practice	A/c> (Director		and
Note: Provide details of the circumstances giving rise to the relevantinterest.	Controller)
Date of change	13 September 2019
No. of securities held prior to change	190,000 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary	Shares
Number acquired	100,000
Number disposed	Nil
Value/Consideration	$0.37
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	290,000 Fully Paid Ordinary Shares
	registered to Watson Practice		Company
	Pty Ltd <Watson Practice A/c>		(Director
	and Controller)

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change	Purchased as part of the Placement as
Example: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back	announced to the market on 24 July 2019and as approved at a General Meeting on 9
	September 2019.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not Applicable
Nature of interest	Not Applicable
Name of registered holder	Not Applicable
(if issued securities)
Date of change	Not Applicable
No. and class of securities to which	Not Applicable
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	Not Applicable
Interest disposed	Not Applicable
Value/Consideration	Not Applicable
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	Not Applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed	Not Applicable
above traded during a+closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the	Not Applicable
trade to proceed during this period?
If prior written clearance was provided, on what date was	Not Applicable
this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011